Aminopyridines: Selective Aurora-A inhibitors

Paola Vianello

Research output: Contribution to journalArticlepeer-review


Aurora inhibitors have been extensively studied as potential novel anticancer agents. At least four compounds are now under clinical evaluation. Banyu discloses aminopyridines and -pyrazines acting as selective Aurora-A inhibitors. The claimed compounds demonstrated low nanomolar activity in the biochemical assay and exhibit a 200-fold specificity on Aurora-A versus Aurora-B.

Original languageEnglish
Pages (from-to)255-261
Number of pages7
JournalExpert Opinion on Therapeutic Patents
Issue number2
Publication statusPublished - Feb 2007


  • Aurora-A
  • Aurora-B
  • Mitosis

ASJC Scopus subject areas

  • Medicine (miscellaneous)
  • Pharmacology
  • Law


Dive into the research topics of 'Aminopyridines: Selective Aurora-A inhibitors'. Together they form a unique fingerprint.

Cite this